Browse the evidence

Type 2 diabetes should be managed as a component of Metabolic Dysfunction Syndrome (MDS) rather than solely as a hyperglycemic disorder, requiring holistic protection of target organs against all MDS-related metabolic disorders.

Do not treat Type 2 Diabetes as just a 'blood sugar problem.' Your risk of organ damage comes from the combination of high blood sugar, high blood pressure, high lipids, and excess weight. Effective management requires addressing all these metabolic factors together to protect your heart, kidneys, and eyes, rather than focusing on glucose alone.

Triple hormone receptor agonist retatrutide (1-12 mg weekly) significantly reduces liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), achieving near-maximal reduction (~80%) at 24 weeks with high doses (8-12 mg).

For patients with MASLD, high-dose retatrutide (8-12 mg weekly) offers a highly effective treatment to significantly reduce liver fat, often normalizing it within 24 weeks. This hormonal intervention addresses the root metabolic drivers of liver fat accumulation more potently than current GLP-1 mono-agonists.

Tirzepatide, a dual agonist of GLP-1 and GIP receptors, achieves significant body weight and glucose control in patients with obesity and type 2 diabetes.

Tirzepatide, which activates both GLP-1 and GIP receptors, is an effective treatment for obesity and type 2 diabetes, leading to significant improvements in body weight and glucose control. It represents a newer class of therapy with promising clinical results.

Multi-targeting agonists (tirzepatide and peptide 20) that activate GIPR, GLP-1R, and GCGR provide superior metabolic efficacy compared to GLP-1 mono-agonists (like semaglutide) by leveraging distinct structural binding modes and retaining glucagon receptor function.

For individuals managing Type 2 Diabetes or Obesity, newer multi-targeting therapies (like tirzepatide) that activate multiple metabolic receptors (GIP, GLP-1, and Glucagon) have demonstrated superior weight loss and glucose control compared to older GLP-1-only medications. This suggests that targeting multiple hormonal pathways simultaneously may offer better clinical outcomes than single-pathway treatments.

Oral semaglutide (7-14 mg/day) provides glucose-lowering and weight-loss effects comparable to subcutaneous formulations, though with lower bioavailability requiring higher doses.

If you prefer pills over injections, oral semaglutide is an option. You must take it on an empty stomach before breakfast, which requires discipline. It uses a higher dose than the shot version to compensate for lower absorption.

Tirzepatide's GIP receptor agonism directly enhances adipocyte glucose uptake and lipid clearance in the fed state by cooperating with insulin, contributing to reduced serum triglycerides without increasing adiposity.

Tirzepatide works partly by helping your fat cells clear sugar and fat from your blood more effectively when you eat, thanks to its GIP receptor activity. This helps lower blood fat levels without making you gain more body fat, complementing the weight loss driven by other mechanisms.

In the fasted state (low insulin), tirzepatide's GIP receptor agonism stimulates lipolysis (fat breakdown) to release stored energy, counter-regulating insulin's storage signal.

When you are not eating, tirzepatide helps your fat cells release stored fat for energy. This happens because the drug's GIP activity stimulates fat breakdown when insulin is low, ensuring your body can access energy stores during fasting periods.

Metformin (850mg twice daily) reduces the incidence of type 2 diabetes by 31% in adults with prediabetes compared to placebo, with effects persisting for up to 22 years.

If you have prediabetes and are over 60, have a BMI over 35, or had gestational diabetes, ask your doctor about Metformin. It is a proven, low-cost way to significantly lower your risk of developing full-blown diabetes, with benefits lasting for decades.

Thiazolidinediones (specifically Pioglitazone) reduce the incidence of type 2 diabetes in individuals with impaired glucose tolerance, but their use is limited by adverse effects such as weight gain, fluid retention, and increased fracture risk.

Pioglitazone can prevent diabetes, but it often causes weight gain and other side effects. It is usually not the first choice; Metformin or GLP-1 medications are typically preferred unless Pioglitazone is specifically indicated for your case.

Tirzepatide improves liver fat content and shows potential efficacy in treating nonalcoholic steatohepatitis (NASH) in patients with type 2 diabetes.

For patients with type 2 diabetes and fatty liver, tirzepatide significantly reduces liver fat content more than insulin therapy, potentially helping manage NASH.

Semaglutide significantly reduces high-sensitivity C-reactive protein (hsCRP) levels in patients with type 2 diabetes compared to placebo and active comparators, indicating an anti-inflammatory effect.

If you have type 2 diabetes, semaglutide (whether injected weekly or taken as a daily pill) significantly lowers hsCRP, a key marker of inflammation linked to heart disease risk. This reduction is greater than with placebo or other common diabetes drugs like exenatide or empagliflozin. While part of this benefit comes from losing weight and lowering blood sugar, there appears to be a direct anti-inflammatory effect. For patients with chronic kidney disease, the trend is positive but not statistically significant compared to placebo in this specific analysis, so discuss risks/benefits with your doctor.

GIP has pleiotropic effects beyond glucose metabolism, including potential benefits for obesity, bone health, and neurodegenerative disorders, making it a candidate for pharmacotherapies.

GIP is not just a blood sugar hormone. It also influences fat storage, bone density, and brain health. This is why new drugs that mimic or modify GIP are being studied for obesity and even neurodegenerative diseases.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces systolic and diastolic blood pressure in patients with type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, tirzepatide (a once-weekly injection) can help lower your blood pressure, which reduces your overall cardiovascular risk. The blood pressure reduction is dose-dependent, meaning higher doses tend to lower BP more.

Tirzepatide reduces inflammatory markers associated with cardiovascular risk, including YKL-40, ICAM-1, leptin, and GDF-15.

Tirzepatide reduces inflammatory markers associated with cardiovascular risk, such as YKL-40, ICAM-1, leptin, and GDF-15. This reduction in inflammation may contribute to the overall cardiovascular benefits of the drug.

Higher cardiorespiratory fitness (CRF) causally reduces the risk of type 2 diabetes, independent of adiposity (BMI), with a 1-SD increase in genetically predicted fitness associated with an 11% lower risk.

Improving your cardiorespiratory fitness (VO2max) directly lowers your risk of type 2 diabetes, regardless of your weight. Focus on exercises that challenge your heart and lungs (like cycling or running) to improve your body's ability to use oxygen, as this has independent metabolic benefits beyond just burning calories.

Semaglutide therapy significantly reduces systemic inflammation, as measured by C-reactive protein (CRP) levels, compared to placebo or other glucose-lowering drugs, regardless of whether the patient has type 2 diabetes or obesity without diabetes.

If you are taking semaglutide for diabetes or weight management, you can expect it to lower your systemic inflammation (measured by CRP). This benefit occurs whether you take the pill or the injection, and whether or not you have diabetes. This anti-inflammatory effect is likely a key reason why semaglutide reduces heart disease risk.

GLP-1 analog treatment (semaglutide and liraglutide) reduces short-term appetite, decreases energy intake, and lowers preference for energy-dense foods (high-fat, sweet, and salty) during the weight loss phase, primarily through mechanisms involving delayed gastric emptying and interaction with brain reward pathways.

GLP-1 medications like semaglutide and liraglutide reduce hunger and change food preferences, particularly reducing cravings for high-fat and sweet foods, during the initial 12-18 months of treatment. This leads to significant weight loss (up to 15%). Side effects like nausea are common but can be managed by starting with lower doses and increasing slowly.

GLP-1 receptor agonists improve liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) by reducing liver fat content, liver stiffness, and liver enzymes (ALT, AST).

If you have fatty liver disease (MASLD) along with diabetes or obesity, GLP-1 medications can help reduce fat in your liver, lower liver enzymes, and improve liver stiffness, potentially slowing or reversing liver damage.

Among GLP-1RAs, Dulaglutide has the lowest risk of causing intolerable gastrointestinal adverse reactions, while Semaglutide and Liraglutide have the highest risk.

If you are experiencing intolerable gastrointestinal side effects on one GLP-1RA (like Semaglutide or Liraglutide), switching to Dulaglutide may reduce these side effects, as it has the lowest risk of intolerable GI reactions among the studied agents.

Real-world users of semaglutide (Wegovy) for weight management rarely follow recommended dose titration protocols, with the majority stopping at or below 1.0 mg rather than reaching the target 2.4 mg dose evaluated in clinical trials.

If you are using Wegovy, know that most people do not reach the maximum 2.4 mg dose. Many stop at 1.0 mg due to side effects or cost. This does not mean the drug isn't working for you, but it may mean your weight loss potential is lower than what is seen in clinical trials. Discuss your dose with your provider to see if escalation is appropriate for your tolerance and financial situation.

In adults with prediabetes, women experience less sustained weight loss and greater loss of fat-free mass and bone mineral content compared to men during long-term lifestyle interventions, despite showing greater improvements in some cardiometabolic markers like fasting glucose and HDL.

Women in this study lost less weight and more muscle/bone than men following the same lifestyle program. To mitigate this, women should prioritize resistance training and protein intake to protect lean mass, and focus on metabolic improvements (like blood sugar and cholesterol) rather than just scale weight, as these may improve even if weight loss is modest.

Women tend to lose more weight than men when treated with GLP-1 receptor agonists (semaglutide, liraglutide) for obesity, despite men often losing more weight with lifestyle interventions alone.

If you are a woman being treated with GLP-1 medications like Wegovy or Saxenda, you are statistically likely to lose more weight than a man on the same drug. This is due to how your body processes the medication. Do not compare your progress to male baselines or lifestyle-only results; your pharmacological response is typically superior.

Tirzepatide 15mg is associated with a higher risk of hypoglycemia compared to GLP-1 receptor agonists, although it has a lower risk of hypoglycemia compared to basal insulins.

If you are on the 15mg dose of Tirzepatide, especially if you also take insulin or sulfonylureas, your risk of low blood sugar (hypoglycemia) is higher than if you were on a standard GLP-1 drug like semaglutide. Monitor your blood sugar closely and discuss dose adjustments with your doctor if you experience symptoms of low blood sugar.

Naltrexone/bupropion reduces food cravings and reward-driven eating by antagonizing opioid receptors, thereby decreasing the subjective delightfulness of energy-dense foods.

If you struggle with intense cravings for sugary or fatty foods, standard dieting may fail because your brain's reward system is driving your intake. Naltrexone/bupropion targets this by blocking opioid receptors, reducing the 'high' you get from these foods. This is prescribed alongside lifestyle changes for obesity management.